全文获取类型
收费全文 | 53553篇 |
免费 | 3425篇 |
国内免费 | 2273篇 |
专业分类
耳鼻咽喉 | 506篇 |
儿科学 | 1223篇 |
妇产科学 | 578篇 |
基础医学 | 8620篇 |
口腔科学 | 857篇 |
临床医学 | 4542篇 |
内科学 | 11616篇 |
皮肤病学 | 507篇 |
神经病学 | 2001篇 |
特种医学 | 1907篇 |
外国民族医学 | 3篇 |
外科学 | 5545篇 |
综合类 | 8517篇 |
现状与发展 | 3篇 |
预防医学 | 2496篇 |
眼科学 | 331篇 |
药学 | 4282篇 |
11篇 | |
中国医学 | 2030篇 |
肿瘤学 | 3676篇 |
出版年
2024年 | 103篇 |
2023年 | 586篇 |
2022年 | 1082篇 |
2021年 | 1366篇 |
2020年 | 1432篇 |
2019年 | 1341篇 |
2018年 | 1394篇 |
2017年 | 1436篇 |
2016年 | 1475篇 |
2015年 | 1656篇 |
2014年 | 2818篇 |
2013年 | 3132篇 |
2012年 | 3118篇 |
2011年 | 3493篇 |
2010年 | 2955篇 |
2009年 | 2876篇 |
2008年 | 3123篇 |
2007年 | 3211篇 |
2006年 | 2891篇 |
2005年 | 2611篇 |
2004年 | 2095篇 |
2003年 | 1851篇 |
2002年 | 1577篇 |
2001年 | 1392篇 |
2000年 | 1282篇 |
1999年 | 1194篇 |
1998年 | 954篇 |
1997年 | 778篇 |
1996年 | 734篇 |
1995年 | 693篇 |
1994年 | 644篇 |
1993年 | 505篇 |
1992年 | 486篇 |
1991年 | 410篇 |
1990年 | 386篇 |
1989年 | 344篇 |
1988年 | 324篇 |
1987年 | 237篇 |
1986年 | 213篇 |
1985年 | 283篇 |
1984年 | 202篇 |
1983年 | 106篇 |
1982年 | 126篇 |
1981年 | 82篇 |
1980年 | 64篇 |
1979年 | 41篇 |
1978年 | 40篇 |
1977年 | 29篇 |
1976年 | 28篇 |
1974年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
目的探讨不同病因肝硬化患者血清脂联素水平的差异。方法采用放射免疫法测定研究对象血清脂联素水平,并比较不同病因肝硬化患者血清脂联素水平的差异。结果乙肝肝硬化组、丙肝肝硬化组脂联素水平与对照组相比较差异无统计学意义(P>0.05);酒精性肝硬化组脂联素水平明显高于对照组(P<0.05);非酒精性脂肪性肝硬化组脂联素水平明显低于对照组(P<0.05)。结论酒精性肝硬化患者血清脂联素水平升高,可能与胰岛素抵抗有关,而血清脂联素水平的降低可能是非酒精性脂肪性肝硬化的始动因素之一。 相似文献
992.
目的研究羟基红花黄色素A(HSYA)与牛血清白蛋白(BSA)和卵清蛋白(OVA)的偶联方法,获得具有免疫原性的羟基红花黄色素A人工抗原。方法通过偶联物透析液的颜色变化、紫外图谱、红外扫描图谱及动物免疫试验来鉴定制备的人工抗原。结果HSYA-BSA人工抗原在紫外扫描中表现出HSYA和BSA的特征吸收峰;在红外扫描中HSYA-BSA具有HSYA特征官能团的吸收峰和氨基酸的特征吸收峰;间接ELISA检测结果显示产生抗HSYA的特异性抗体,血清效价可达1∶3 200;标准曲线方程计算得BSA和HSYA的结合率是1∶50。结论通过直接偶联法成功制备出具有免疫原性的羟基红花黄色素A人工抗原。 相似文献
993.
目的探讨膝骨关节炎(knee osteoarthritis,KOA)患者膝关节液中IL-17表达水平。方法用双抗体夹心ELISA法测定37例(41膝)KOA患者与24例(24膝)志愿者膝关节液中IL-17浓度并比较两组差异。将KOA患者按综合评分法分为轻(13膝)、中(19膝)、重(9膝)三组,比较三组患者膝关节液中IL-17浓度的差异。结果KOA患者膝关节液中IL-17浓度为156.76±112.78pg/ml,明显高于对照组31.67±18.74pg/ml(P〈0.01)。轻、中、重三组患者膝关节液中IL-17的浓度分别为50.16±24.15pg/ml、154.63±47.39pg/ml、314.83±105.89pg/ml,呈现出随着病情分级逐渐加重而IL-17表达水平逐渐增高的趋势(P〈0.01)。结论IL-17作为一种前炎症细胞因子,参与了KOA疾病的诱发、触发了病理改变、加快了病情的进展。IL-17可作为判断KOA临床病情、预后的免疫学指标之一。对IL-17的研究将有助于进一步在分子水平阐明KOA的发病机制,为临床诊断和治疗KOA提供新的思路。 相似文献
994.
目的初步探讨APC蛋白表达在衰减型家族性腺瘤性息肉病诊断中的意义。方法疑似衰减型家族性腺瘤性息肉病67例,散发性大肠腺癌30例,正常大肠粘膜30例作为正常对照。采用免疫组化法检测各组中APC蛋白表达水平。结果疑似衰减型家族性腺瘤性息肉病组APC蛋白阴性表达率26.87%(18/67),其中10枚≤结肠腺瘤数目〈100枚者11例,2枚≤结肠腺瘤数目〈10枚并伴发胃底腺息肉或十二指肠腺瘤者7例;散发性大肠腺癌组中APC蛋白阴性表达率为43.33%(13/30);正常大肠粘膜组未发现一例APC蛋白阴性表达。结论伴发胃底腺息肉或十二指肠腺瘤的2枚≤结肠腺瘤数目〈100枚且APC蛋白表达阴性者可以诊断为AFAP。不伴胃底腺息肉或十二指肠腺瘤的10枚≤结肠腺瘤数目〈100枚者,APC蛋白表达阴性只能作为AFAP的辅助诊断,应调查其家族史,排除APC基因体细胞突变情况。APC蛋白阳性表达的患者不能除外AFAP的可能。 相似文献
995.
《Respiratory investigation》2021,59(6):837-844
BackgroundUnilateral upper-lung field pulmonary fibrosis (upper-PF), which is radiologically consistent with pleuroparenchymal fibroelastosis, develops after thoracic surgery. In most patients with unilateral upper-PF, aberrant intra-/extra thoracic air commonly emerges and an autopsy shows chronic pleuritis, which indicates that pleural involvement is associated with upper-PF development. If so, there may be patients with unilateral upper-PF who have a history of pleural involvement, including tuberculous pleurisy (TP) or asbestos exposure (AE). This study aimed to examine this supposition.MethodsWe examined the radiological reports of all consecutive patients from 2012 to 2018 to investigate whether there were patients having unilateral upper-PF and a history of TP or AE.ResultsEight patients were included in the study. Five patients had a history of TP, and the remaining three had that of AE. All patients were men and had respiratory symptoms, and seven patients presented with restrictive ventilatory impairment. The interval between TP or last AE and upper-PF development was long, with a median of over 20 years. The upper-PF lesion was commonly located in the right lung, and aberrant intrathoracic air was observed in five patients during their clinical course. Additionally, the upper-PF lesion transformed into a cystic lesion in six patients, which resulted in Aspergillus infection in two patients. The prognosis was poor, with a median overall survival of 38 months.ConclusionsUnilateral upper-PF developed even in patients with a history of pleural involvement. Our results indicate that pleural involvement plays an important role in the development of unilateral upper-PF. 相似文献
996.
Fabián Matías Caro María Laura Alberti Federico Campins Juan Ignacio Enghelmayer Martín Eduardo Fernández Diana Lancellotti Tulio Papucci Javier Adrián Sebastiani Francisco Paulin 《Archivos de bronconeumologia》2019,55(2):75-80
Introduction
Pirfenidone was the first antifibrotic drug approved in Argentina for idiopathic pulmonary fibrosis (IPF). Outcomes in real life may differ from the results of clinical trials. The primary endpoint was to study the tolerance of pirfenidone in real life. Secondary endpoints were to analyze effectiveness and reasons for discontinuation.Materials and methods
Retrospective observational study conducted in four specialized centers in Argentina. We analyzed the medical records of patients with IPF who received pirfenidone between June 2013 and September 2016. Adverse events (AE) and the variables that could influence these results were analyzed. Forced vital capacity (FVC%) parameters were also compared between the pre-pirfenidone and post-pirfenidone periods.Results
Fifty patients were included, 38 (76%) men, with mean age (SD) 67.8 (8.36) years. Mean (SD) exposure to pirfenidone was 645.68 (428.19) days, with a mean daily dose (SD) of 2064.56 mg (301.49). Nineteen AEs in 15 patients (30%) were reported: nausea (14%), asthenia (10%) and skin rash (8%). A total of 18 patients (36%) interrupted treatment, only 1 definitively. The most frequent reason for discontinuation was failure of suppliers to provide the drug (9 subjects; 18%). We compared the evolution of FVC% between the pre-pirfenidone and post-pirfenidone periods, and found a mean (SD) FVC% decline of 4.03% (7.63) pre-pirfenidone and 2.64% (7.1) post-pirfenidone (P=.534).Conclusions
In our study, pirfenidone was well tolerated and associated with a reduction in FVC decline, although without reaching statistical significance. 相似文献997.
Li Zhang Yuli Kang Shujun Chen Li Wang Min Jiang Leihong Xiang 《Journal of dermatological science》2019,93(2):92-100
Background
Vitiligo is an autoimmune disease with varying pathological features. Activation of the CCL20-CCR6 axis plays an important role in chronic inflammatory diseases. However, whether CCL20-CCR6 and Th1/17 cells are indicative of active vitiligo is unclear.Objective
To investigate the potential role of CCL20 and the involvement of Th1/17 and Tc1/17 cells in the mechanism in vitiligo.Methods
One hundred patients with vitiligo, and 20 healthy controls were included. The serum and blister fluid IL-17, IFN-γ, CCL20, and CXCL10 were studied using enzyme-linked immunosorbent assays. The numbers of Th1/17 cells and Tc1/17 cells in circulation were quantified using flow cytometry. CCR6 mRNA in peripheral blood mononuclear cells (PBMCs) was analyzed by real-time polymerase chain reaction and the protein level was confirmed by western blotting. CCR6 and CCL20 expression in lesions was analyzed by immunohistochemistry.Results
The serum CCL20 level was significantly elevated in patients with vitiligo. The level of serum CCL20 was higher in active than in the stable stage, which correlated positively with the Vitiligo European Task Force spreading score and the Vitiligo Area Scoring Index score. Patients with active vitiligo had elevated numbers of circulating Th1/17 cells and Tc1/17 cells, and upregulated expression of CCR6 in PBMCs and lesions. After effective treatment, the level of CCL20 in sera and blister fluid was significantly decreased, as were the numbers of circulating Th1/17 cells and Tc1/17 cells.Conclusion
CCL20 might be a vital biomarker of active vitiligo, and circulating Th1/17 and Tc1/17 cells are involved in the pathogenesis of vitiligo. 相似文献998.
999.
1000.
Joanna Leszczyńska Anna Diowksz Agata ??cka Ma?gorzata Bryszewska Katarzyna Wolska Wojciech Ambroziak 《Food and Agricultural Immunology》2009,20(2):139-145
Results of the research on the lowering of allergenicity of wheat flour fermented using homo- and heterofermentative lactic acid bacteria and mixed cultures with yeast were discussed. The gliadins’ immunoreactivity was measured using the indirect non-competitive enzyme-linked immunosorbent assay method. The biggest decrease of the immunoreactivity of gliadin fraction was observed in the case of fermentation performed with the use of mixed cultures of lactic acid bacteria and yeast. This way of wheat flour modification seems to be promising, because fermentation is a natural process causing not only lowering of the allergenicity, but also improving organoleptic and nutritional values of obtained products. 相似文献